Scholarlink

<p>Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月16日

查看全文
  • Lingping Xie,
  • Tianhai Du,
  • Chao Wang

摘要

Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.